Navigation Links
Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
Date:11/19/2010

NEW YORK, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival (PFS) when compared to sorafenib, in the study population.  Consistent with previous analyses, axitinib demonstrated a generally manageable safety profile in this study.

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

"It is gratifying that in this trial axitinib provided significant benefit to patients with advanced RCC whose disease had progressed after 1st-line therapy," said Dr. Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs for Pfizer's Oncology Business Unit.  "These results provide insight into the potential value of axitinib as part of a sequential treatment approach in patients with advanced RCC.  We will work with health authorities to determine possible filing options for axitinib for use in patients with advanced RCC."

Each year, approximately 210,000 people worldwide are diagnosed with kidney cancer and nearly 102,000 people are expected to die from the disease.  Within the last five years, great advances have been made in the treatment of patients with advanced RCC, the most prevalent form of kidney cancer.  However, five-year survival rates for patients with advanced RCC remain low, at around 20 percent.

About the Investigational Agent Axitinib

Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3.  VEGF receptors 1, 2 and 3 appear to have roles in tumor growth, vascular angiogenesis and metastatic progression of cancer (the spread of
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pfizer Launches New Advil® Congestion Relief and Offers 100 Holiday Shoppers Literal Decongestion From Black Friday Crowds
2. Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
3. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
4. Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
5. Pfizer Declares an 18-Cent Fourth-Quarter 2010 Dividend
6. Pfizers Lyrica® (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan
7. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
8. Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil
9. Biocon and Pfizer Enter Into Global Commercialization Agreement
10. Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
11. Pfizer Completed Acquisition of FoldRx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon Solution, ... advanced memory and analog IC solutions, today announced that ... July 24, 2014, at 7:00 a.m. Pacific Time (10:00 ... for the fiscal 2014 third quarter ended June 30, ... telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time on ...
(Date:7/10/2014)... JORDAN, Utah , July 10, 2014  BC ... solutions, and MiE America , Inc., a leading ... have entered into a long-term agreement naming BC Technical ... the US. MiE and BC Technical ... strategic agreement to establish BC Technical as the service ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 /PRNewswire/ ... three-quarters of surveyed infectious disease (ID) specialists are ... Medicines Company,s Orbactiv (oritavancin) for use as OPAT, ... to prescribe these agents to their hospital inpatients. ... percent) of OPAT patients are initiated on OPAT ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... ST. LOUIS , Feb. 1 Stereotaxis (Nasdaq: ... featured Dr. Mauricio Arruda , a leading electro-physiologist ... in Cleveland, Ohio , performing a live cardiac ablation ... The patient was a 69 year old woman who suffered ...
... BRISBANE, Calif. , Feb. 1 InterMune, ... Food and Drug Administration,s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) ... for pirfenidone on March 9, 2010 .  Pirfenidone is ... idiopathic pulmonary fibrosis (IPF).   , "There is an urgent ...
Cached Medicine Technology:Stereotaxis System Procedure Featured on NBC's The TODAY Show 2InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 2InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 3InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 4InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 5
(Date:7/10/2014)... THURSDAY, July 10, 2014 (HealthDay News) -- Nature, not ... intelligence of individual chimpanzees, a new study finds. ... it comes to cognitive [thinking] abilities in chimpanzees," William ... Atlanta, said in a news release from the journal ... give insight into the evolution of intelligence in humans, ...
(Date:7/10/2014)... THURSDAY, July 10, 2014 (HealthDay News) -- Men who ... aggressive prostate cancer, a new study suggests. But ... several urologists not involved with the study said more ... are truly accurate. For the study, Harvard researchers ... were followed for 24 years, starting in 1986. During ...
(Date:7/10/2014)... More than 200 experts on aggression, who research issues ... attend the 21st World Meeting of the International Society ... Hotel, July 15-19. , Georgia State University is hosting ... year on alternating continents. , "We are excited to ... different countries, which will help produce fresh ideas about ...
(Date:7/10/2014)... of Health and Human Services (HHS) has announced a ... Seidman Cancer Center totaling $4.7 million to support a ... with complex cancer. , Titled "Evidence-Conformant Oncology Care," ... UH to enhance care for adult cancer patients with ... health care utilization. , "We believe that ...
(Date:7/10/2014)... shown that more severe illness and even death are ... infection after developing influenza. Now, however, a team of ... if you reverse the order of infection, the bacteria ... protect against a bad case of the flu. ... which is described as a bacterial virulence factor, might ...
Breaking Medicine News(10 mins):Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2
... ,Hidden Health Tax, is the Undisclosed Premium Surcharge that Pays ... People Join the Ranks of the Uninsured, the ,Hidden Health ... Higher in 2009WASHINGTON, May 28 The so-called ... $1,017 in 2008 according to a report released today by ...
... Elsevier, would like to announce the publication of ... Treatment by Peter Miller, PhD. , The ... the field of addictions treatment is leading to ... based solely on clinical intuition rather than hard ...
... 2009) Kevin Bruhn, PhD, is the winner of the ... at nurturing excellence and providing support for a young scientist ... to LA BioMed in 2005 after receiving his PhD in ... Los Angeles in 2004 and completing a postdoctoral fellowship in ...
... BIRMNGHAM, Ala. An experimental drug derived from cottonseed ... widely considered the most lethal brain cancer, said researchers ... The new results are from a Phase II clinical ... compound in cottonseed that overcomes the abnormal growth patterns ...
... fractional laser was featured today on NBC,s Today ... for scars. During the broadcast, triplets who were severely ... story and discussed recent treatments with the Lumenis UltraPulse ... and DeepFX technologies, the triplets Jordan, Trae and Chandra ...
... Deliciously Cool, Smooth Drink While It,s HotBATTLE CREEK, Mich., May 28 ... season doesn,t feature the bells and whistles of most sought-after new ... to get their hands on it just the same. ... (R) brand is introducing the brand,s first ...
Cached Medicine News:Health News:'Hidden Health Tax' for Family Health Care Coverage Climbed to $1,017 in 2008 2Health News:'Hidden Health Tax' for Family Health Care Coverage Climbed to $1,017 in 2008 3Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 2Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 3Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 4Health News:Special K(R) Brand Shakes Things Up with New Weight-Management Protein Shake 2Health News:Special K(R) Brand Shakes Things Up with New Weight-Management Protein Shake 3Health News:Special K(R) Brand Shakes Things Up with New Weight-Management Protein Shake 4
...
... Miditron Junior II ... urinalysis analyser for standardised ... hardware and software features ... high performance and convenience ...
... The Assistant Free ... retractors utilizing Velcro® straps. ... of the surgeon's operative ... personnel. Three retractor styles ...
... for four corner fusion of the capitate, ... hand. The plate is intended for use ... of function due to SLAC and SNAC ... rheumatoid arthritis. When combined with the specially ...
Medicine Products: